Research Letter

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases

Author Affiliation(s)



1. Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799. DOI:10.1111/jdv.14386. PMID: 28585342. 2. Uppala R, Tsoi LC, Harms PW, et al. "Autoinflammatory psoriasis"-genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021;18(2):307-317. DOI:10.1038/s41423-020-0519-3. PMID: 32814870. PMCID: PMC8027616. 3. Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf. 2020;19(8):969-980. DOI:10.1080/14740338.2020.1785427. PMID: 32615817. 4. Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study. J Am Acad Dermatol. 2019;80(5):1344-1352. DOI:10.1016/j.jaad.2019.01.066. PMID: 30716404. 5. Borroni RG, Malagoli P, Gargiulo L, et al. Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study. Acta Derm Venereol. 2021;101(11):adv00605. DOI:10.2340/actadv.v101.283. PMID: 34596230. PMCID: PMC9455321. 6. Gargiulo L, Pavia G, Valenti M, et al. Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study. Dermatol Ther (Heidelb). 2022;12(5):1263-1270. DOI:10.1007/s13555-022-00726-w. PMID: 35460018. PMCID: PMC9110615.

Send mail to Author

Send Cancel